BIOSPAIN 2026

A silent storm is sweeping the globe: chronic kidney failure touches more than 850 million lives, ranks ninth among causes of death, and affects roughly 10% of the world’s population. In Spain alone, 15% of adults live with chronic kidney disease and about 68,000 people require dialysis or transplant to survive. Spain stands out as a beacon of transplant medicine — performing more than 6,000 kidney transplants a year and consistently leading the world in donor rates and clinical outcomes. Yet even a success story must evolve. To truly conquer organ shortages, extend long-term graft survival, and free patients from lifelong immunosuppression, bold innovation is essential. The horizon is already changing: xenotransplantation, advanced machine perfusion for organ preservation, robotic-assisted surgery (an area where Spain is a trailblazer), and AI-driven donor–recipient matching are reshaping what’s possible. Transplantation is re-emerging as a frontier of therapeutic invention, offering a rare opportunity to recast how drugs and biologics are developed for complex, high-stakes indications. Spain’s dense, high-volume clinical landscape offers an exceptional proving ground to accelerate next-generation drug development. By weaving together model-informed drug development, adaptive and innovative trial designs, and early regulatory alignment, we can shorten timelines, reduce development risk, and create more efficient clinical programs. The complexity of transplant studies — patient heterogeneity, long timelines, and shifting endpoints — demands this kind of nimble, collaborative approach. What’s needed now is stronger partnership between clinical centers, industry, regulators, and patient organizations to build an integrated ecosystem for transplant-focused innovation. The upcoming round table will explore how Spain can leverage its clinical excellence to become a global reference for transplant drug development, and how a forward-looking, coordinated strategy can turn today’s promise into tomorrow’s cures.